|
Synonyms: AOC 1001 | AOC-1001 | del-desiran
Compound class:
Nucleic acid
Comment: Delpacibart etedesiran (AOC 1001) is structurally a monoclonal antibody (mAb)-oligonucleotide conjugate (AOC) in which the mAb binds the transferrin receptor (TFRC;) for targeted delivery of a duplex small interfering RNA (siRNA) payload that degrades the mRNA that encodes DM1 protein kinase (DMPK) [1].
This entry provides information on the siRNA as the component that mediates the agent's intended pharmacodynamic effect. Further details about the parental anti-TFRC mAb are provided in the delpacibart entry. To improve pharmacokinetics and RNA binding the nucleotides in etedesiran are chemically modified (2'-O-methyl/2'-MOE monomers), with a mixed phosphorothioate/phosphate backbone. The mAb is attached to the siRNAs via malemide linkers at Cys-R positions on the passenger strands. Delpacibart etedesiran is proposed to reduce the global splicing defects that arise from toxic gain-of-function DMPK transcript accummulation in myocytes in myotonic dystrophy type 1. |
| No information available. |
Summary of Clinical Use ![]() |
| Delpacibart etedesiran (AOC 1001) was progressed as a clinical candidate for its potential to treat myotonic dystrophy type 1. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05027269 | Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients | Phase 1/Phase 2 Interventional | Avidity Biosciences, Inc. | The MARINA study | 1 |
| NCT05479981 | Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients | Phase 2 Interventional | Avidity Biosciences, Inc. | The MARINA-OLE study | |
| NCT07008469 | Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | Phase 3 Interventional | Avidity Biosciences, Inc. | The HARBOR-OLE study | |
| NCT06411288 | Global Study of Del-desiran for the Treatment of DM1 | Phase 3 Interventional | Avidity Biosciences, Inc. | The HARBOR study | |